As reported on Pharma Phorum, Roivant Sciences and its subsidiary Priovant Therapeutics have received U.S. Food and Drug Administration (FDA) approval for Lisraya (brepocitinib), marking the first targeted treatment specifically…
As reported on Business Wire, AstraZeneca has finalized its previously announced licensing agreement with Dizal Pharmaceutical, gaining exclusive worldwide rights to develop and market ZEGFROVY (sunvozertinib), an oral, irreversible epidermal…
Treating acute ischemic strokes involves a precarious clinical balance: physicians must dissolve arterial clots to save brain tissue without triggering catastrophic intracranial hemorrhaging. To address the severe bleeding risks associated…
Editor's Note: Patient Worthy is honored to share the following article, originally published by our friends at CURE SYNGAP1. To see the article in its original format, please click here.…
As reported on PharmaBiz, a new study published in Cell Stem Cell highlights a promising approach to cancer immunotherapy that combines stem cell technology with personalized tumor targeting. Researchers from…
As reported on BioPharmaDive, Moderna captured attention this week with two major developments: a multibillion-dollar financing initiative aimed at expanding its oncology portfolio and regulatory clearance for its latest COVID-19…
As reported on PR NewsWire, Orsini has been named a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral treatment recently approved by the US Food and Drug Administration…
As reported on Healio, the phase 3 CARDIO-TTRansform study, the largest clinical trial conducted to date in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), found that adding eplontersen to contemporary…
Editor's Note: Patient Worthy is honored to share this article, originally written by Danviel Villarte . Danviel is part of the Outreach Team at Receptive, where he helps build and…
As reported on The Hill, Vitruvias Therapeutics has initiated a voluntary nationwide recall of a specific lot of thyroid medication after testing indicated the tablets may contain higher-than-labeled potency, according…
As reported on BioSpace, Vera Therapeutics’ newly approved IgA nephropathy (IgAN) treatment, Trutakna, is showing early evidence that it may help preserve kidney function, a benefit that had recently drawn…
As reported on GlobeNewswire, a newly published set of expert consensus recommendations is seeking to improve the care experience for children diagnosed with neuroblastoma and the families who support them.…
As reported on Newsweek, a novel experimental treatment for Guillain-Barré syndrome (GBS) may represent a major advance for patients living with the rare neurological disorder. New findings released by biotechnology…
As reported on CNN, the U.S. Food and Drug Administration (FDA) has approved the first gene therapy designed to treat a rare inherited form of congenital deafness, marking a major…
As reported on MedicalXpress, researchers have reported that urolithin A, a compound derived from gut metabolism and available as an over-the-counter supplement, enhanced the effectiveness of the immunosuppressant cyclosporine in…
As reported on Fierce BioTech, the U.S. Food and Drug Administration has granted approval to Lantheus’ positron emission tomography (PET) imaging agent Tauklarify (MK-6240), expanding diagnostic options for the assessment…
As reported on BioSpace, the U.S. Food and Drug Administration has approved Regeneron’s Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes bone to…
As reported by allsci, China’s National Medical Products Administration (NMPA) has granted conditional approval to TransThera Sciences’ Yochanra (tinengotinib) for adults with unresectable, advanced, or metastatic cholangiocarcinoma (CCA) carrying FGFR2…
As reported by PharmaBiz, Zydus Lifesciences has announced the launch of Revahale (revefenacin), a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).…
As reported on BioSpace, AstraZeneca has discontinued a pivotal Phase 3 trial evaluating its investigational bispecific antibody volrustomig in advanced non-small cell lung cancer (NSCLC) after an interim analysis indicated…
New observational research suggests that addressing obesity alongside inflammatory joint disease could improve treatment outcomes for people with psoriatic arthritis (PsA). As reported on MedIndia, a recent propensity score-matched analysis…
As reported on News Medical, researchers are highlighting a new class of therapies that could improve outcomes for people living with primary biliary cholangitis (PBC), a chronic autoimmune liver disease…
Researchers at MIT have identified a potential new approach to reducing lung cancer risk by targeting caspase-1, an enzyme involved in inflammation. Findings published in Science Advances suggest that blocking…
A recent study shared by The Lancet shows that a first-in-class investigational therapy targeting neurotrophin-3 (NT-3) significantly reduced pain and improved function in patients with knee osteoarthritis (OA), according to…
As reported on Fierce Biotech, Samsung Electronics has obtained clearance from the U.S. Food and Drug Administration (FDA) for software features that transform select Galaxy Buds earbuds into over-the-counter (OTC)…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
